Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

NCT05124210 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
8
Enrollment
INDUSTRY
Sponsor class

Stopped Decrease in in-vitro neutralization of study drug against circulating SARS-CoV-2 variants

Conditions

Interventions

Sponsor

GlaxoSmithKline

Collaborators